/
Other
Immunogenicity
99
Pipeline Programs↗
134
Active Trials↗
134
Companies Involved↗
Immunogenicity is a moderately active landscape with 99 programs across 134 companies. The most active players are Sanofi, AstraZeneca, LiteVax BV. 28 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 143
Phase 220
Phase 328
Approved
No programs
Analysis
Modality Breakdown
40programs
Small molecule2050%
Vaccine1435%
Monoclonal antibody38%
Protein / enzyme25%
RNA therapy13%
Modality classified for 100% of 99 pipeline programs.
Analysis
Trial Status
1,635
clinical trials
Completed1,289 · 79%
Unknown status126 · 8%
Recruiting50 · 3%
Terminated49 · 3%
Active, not recruiting48 · 3%
Withdrawn34 · 2%
Other39 · 2%
Clinical Trials
Trial Activity
1635 trials
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
Recruiting·—·Phase 3·NCT07003984·720 enrolled
RSV Immunogenicity Study in the Elderly (RISE)
Recruiting·—·Phase 3·NCT07203365·65 enrolled
Page 1 of 109
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)